Zentalis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZNTL research report →
Range $5 – $10
Price Chart
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations.
- CEO
- Julia Marie Eastland
- IPO
- 2020
- Employees
- 106
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ZNTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $133.64M
- P/E
- -0.71
- Fwd P/E
- 207.63
- PEG
- -0.14
- P/S
- 0.00
- P/B
- 0.56
- EV/EBITDA
- -1.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -75.82%
- ROIC
- -62.29%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-152,808,000
- Net Income
- $-137,060,000+17.4%
- EPS
- $-1.91+18.0%
- OCF Growth
- +26.7%
- FCF Growth
- +26.8%
- 52W High
- $6.95
- 52W Low
- $1.30
- 50D MA
- $2.30
- 200D MA
- $3.37
- Beta
- 1.93
- RSI (14)
- 24
- Avg Volume
- 1.26M
No earnings-call transcripts are available for ZNTL yet.
- Free Float
- 70.9%
- Shares Outstanding
- 98.27M
- Float Shares
- 69.63M
of shares held by institutions
123 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Squadron Capital Management LLC | 6.83M | ▲ 3.13M |
| Citadel Advisors LLC | 4.49M | ▲ 2.19M |
| 5am Venture Management, LLC | 3.95M | 0 |
| Blackrock, Inc. | 3.91M | ▲ 159.09K |
| Adar1 Capital Management, LLC | 3.76M | ▲ 3.11M |
| Vanguard Capital Management LLC | 3.52M | ▲ 687.85K |
| Acadian Asset Management LLC | 3.06M | ▲ 374.22K |
| Vanguard Group Inc | 2.86M | ▼ 48.81K |
| Two Sigma Investments, LP | 2.80M | ▼ 223.55K |
| Patient Square Capital LP | 2.01M | ▲ 2.01M |
| Seven Fleet Capital Management LP | 1.50M | ▲ 1.19M |
| Renaissance Technologies LLC | 1.50M | ▼ 110.73K |
Held by 109 ETFs
Biggest fund positions in ZNTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Bruns Ingmar | other | 9,727 |
| Aug 14, 26 | WALTERS GROUP | buy | 4,335,000 |
| Jun 16, 26 | Johnson David Michael | other | 57,100 |
| Jun 16, 26 | Skvarka Jan | other | 57,100 |
| Jun 16, 26 | Walker Luke Nathaniel | other | 57,100 |
| Jun 16, 26 | Kariuki Enoch | other | 57,100 |
| Jun 16, 26 | Myers Scott Dunseth | other | 57,100 |
| May 26, 26 | Campbell Shannon | other | 114,200 |
| May 22, 26 | Campbell Shannon | other | 0 |
| Feb 6, 26 | Bruns Ingmar | sell | 2,962 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZNTL coverage
Recent articles, reports, and earnings notes.
No research on ZNTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZNTL report →Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
globenewswire.com · Nov 9
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 3
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 2
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
globenewswire.com · Oct 23
HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)
defenseworld.net · Oct 19
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
globenewswire.com · Oct 18
Johnson & Johnson (NYSE:JNJ) & Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head-To-Head Contrast
defenseworld.net · Oct 11
Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)
defenseworld.net · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.